Add to Calendar 3/19/2019 8:00:00 AM 3/19/2019 10:00:00 AM The Art of the Pivot: How Companies Have Successfully Made Strategic Shifts Biotech and pharma companies often face a fork in the road where they must make a strategic directional decision to ensure value creation for shareholders and in some cases viability of the product or company. Although this happens fairly frequently in large, multinational companies, it is much more noticeable in small to mid-sized organizations where head counts and pipeline are much more concentrated. These decisions may involve a change of therapeutic focus, developing a device or platform instead of a drug, dropping other product development programs in order to focus on a priority product, downsizing, etc. Our panel of experts will discuss their own experiences in the art of the pivot and how these strategic moves, made at the right time and with the right leadership can be crucial to success. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
President and CEO, Lyra Therapeutics
Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.